Clinical Trial Update: Study of Pegylated Human Recombinant Arginase for Liver Cancer (BCT-100-002) [Phase 1, Phase 2]

View source ↗

Summary

This document reports the completed Phase 1/2 clinical trial of BCT-100 (pegylated human recombinant arginase) for hepatocellular carcinoma, conducted by Bio-Ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• BCT-100 (pegylated human recombinant arginase)

Snippet

Sponsor: Bio-Cancer Treatment International Limited | Conditions: Neoplasm, Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: COMPLETED